



Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. *Blood*. 2017;130(16):1800-1808.

In Table 1 on page 1803 in the 19 October 2017 issue, there are errors in the row labeled "Indeterminate/missing." Also, the footnote symbol "‡" should be added to the row heading "Total no. of lines of chemotherapy and ASCT received, %" and corresponding text should be added as is shown in the corrected footnote. The row's subheading "2" should read "2-3" and the subheading "3" should read "≥4." The last row should be deleted. The corrected Table 1 is shown below.

Table 1. Baseline patient characteristics

Characteristic	MDACC (n = 165)	IA/MC (n = 82)	LY.12 (CCTG) (n = 219)	CORAL (LYSARC) (n = 170)	Pooled (N = 636)
Median age, y (range)	56 (20-81)	60 (20-80)	54 (24-70)	54 (19-65)	55 (19-81)
Male sex, %	64	62	61	69	64
Primary diagnosis, %					
DLBCL*	76	89	84	100	87
PMBCL	1	0	5	0	2
TFL	3	0	10	0	4
Indeterminate/missing	19	11	1	0	7
ECOG PS, %					
0-1	42	72	89	84	73
2-4	10	24	11	15	14
Missing	49	4	0	1	13
Disease stage, %					
I-II	18	20	33	32	27
III-IV	82	79	67	67	72
Missing	0	1	0	1	<1
IPI risk classification, %†					
Low risk	5	22	36	32	25
Low-intermediate risk	7	31	30	29	24
High-intermediate to high risk	23	48	35	34	33
Missing or incompletely assessed	65	0	0	5	18
Refractory category, %					
Primary refractory	0	24	51	28	28
Refractory to ≥ second-line therapy	90	51	21	46	50
Relapsed ≤12 mo post-ASCT	10	24	28	26	22
Total no. of lines of chemotherapy and ASCT received, %‡					
1	0	24	51	28	28
2-3	90	50	21	46	49
≥4	0	1	0	0	<1

CCTG, Canadian Cancer Trials Group; LYSARC, Lymphoma Academic Research Organization.

*In the CORAL (LYSARC) study, the disease subtype for 96 patients was not available; per the study inclusion criteria, patients were to have DLBCL.

†IPI was determined at diagnosis for MDACC and IA/MC and at randomization for LY.12 and CORAL study patients; low risk, 0-1 point; low-intermediate risk, 2 points; high-intermediate to high risk, ≥3 points.

‡Includes the 78% of patients who were refractory to chemotherapy and excludes those who relapsed post-ASCT.

Continued on 588

Downloaded from http://ashpublications.net/blood/article-pdf/131/5/587/1466199/blood17775.pdf by guest on 02 June 2024

On page 1806 in line 12 of the paragraph in the left column, the citation of reference 31 should be deleted. In line 16 of the same paragraph, the citation of reference 8 should be replaced with a citation of reference 37. In the reference list on page 1808, reference 37 should be added as follows:

37. Costa LJ, Maddocks K, Epperla N, et al. Diffuse large B-cell lymphoma with primary treatment failure: ultra-high risk features and benchmarking for experimental therapies. *Am J Hematol*. 2017;92(2):161-170.

The errors have been corrected in the online version, which now differs from the print version.

DOI 10.1182/blood-2017-11-817775

© 2018 by The American Society of Hematology